Related Experiment Videos
Comparative effectiveness of low-dose versus high-dose vitamin D on bone metabolic markers in preterm infants: a
Shanshan Zeng1, Binyuan Yu1, Yingying Bao1
1Department of Neonatology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Insights
Vitamin D (VD) supplementation for preterm infants showed similar serum 25(OH)D levels at 4 weeks regardless of 500 or 900 IU/day dose. Higher alkaline phosphatase was noted in some infants receiving the higher VD dose.
Area of Science:
- Neonatology
- Pediatric Nutrition
- Endocrinology
Background:
- Vitamin D (VD) supplementation is crucial for preterm infants' bone health, but optimal dosing lacks consensus.
- Limited evidence compares common VD regimens for early biochemical outcomes in infants <32 weeks gestation.
- This study addresses the variability in VD supplementation guidelines for vulnerable preterm infants.
Purpose of the Study:
- To compare the efficacy of 500 IU/day versus 900 IU/day VD supplementation.
- To evaluate serum 25-hydroxyvitamin D [25(OH)D] levels and bone metabolic markers.
- To assess early biochemical outcomes in preterm infants (<32 weeks gestation) within the first postnatal month.
Main Methods:
- Retrospective cohort study of preterm infants (<32 weeks gestation) receiving 500 IU/day (n=124) or 900 IU/day (n=115) VD.
- Serum 25(OH)D measured by LC-MS/MS; calcium, phosphorus, and ALP assessed at birth and 4 weeks.
- Exclusion of infants with major anomalies, severe organ dysfunction, or protocol non-adherence.
Main Results:
- No significant difference in serum 25(OH)D concentrations at 4 weeks between 500 IU/day and 900 IU/day VD groups (31.46 vs 32.52 ng/mL).
- Alkaline phosphatase (ALP) was higher in the 900 IU/day group for infants born at 28+0 to 31+6 weeks' gestation.
- Calcium, phosphorus levels, and major neonatal complication rates were similar between the two VD supplementation groups.
Conclusions:
- Both 500 IU/day and 900 IU/day VD supplementation achieve similar serum 25(OH)D levels in preterm infants by 4 weeks.
- Higher VD dose (900 IU/day) may be associated with increased ALP in specific preterm subgroups.
- Findings are limited to the first postnatal month, highlighting the need for long-term outcome data.
Background:
Vitamin D (VD) supplementation is routinely used in preterm infants to support bone mineralization, but recommended doses vary across guidelines and clinical practice. In infants born at less than 32 weeks' gestation, evidence comparing commonly used regimens remains limited, particularly for early biochemical outcomes during the first postnatal month. This study aimed to compare 500 versus 900 IU/day VD supplementation for serum 25-hydroxyvitamin D [25(OH)D] and bone metabolic markers in this population.
Methods:
This single-center retrospective cohort study included preterm infants with a gestational age of less than 32 weeks who were discharged from the Neonatal Intensive Care Unit of the Women's Hospital, Zhejiang University School of Medicine between April 1, 2024 and May 31, 2025. Infants received either 500 IU/day (n=124) or 900 IU/day (n=115) of VD starting during postnatal days 5 to 8. Eligible infants had no prior VD supplementation and available 4-week outcome data; infants with major congenital anomalies, severe hepatic or renal dysfunction, major metabolic disorders, or protocol non-adherence were excluded. Serum 25-hydroxyvitamin D [25(OH)D] was measured by liquid chromatography-tandem mass spectrometry. Calcium, phosphorus, and alkaline phosphatase (ALP) were assessed within the first week after birth and again at 4 weeks of postnatal age. Major neonatal complications were also recorded.
Results:
Baseline characteristics were similar between groups, including gestational age, birth weight, parenteral nutrition duration, and first-week calcium, phosphorus, and ALP concentrations (all P>0.05). At 4 weeks of postnatal age, serum 25(OH)D concentrations were similar between the 500 IU/day and 900 IU/day groups (median (interquartile range), 31.46 (26.18-39.52) ng/mL versus 32.52 (24.94-38.57) ng/mL; P=0.771), and VD status distribution did not differ significantly. In gestational-age-stratified analysis, ALP was higher in the 900 IU/day group among infants born at 28+0 to 31+6 weeks' gestation, whereas no clear between-group difference was observed in infants born at less than 28 weeks' gestation. Calcium and phosphorus concentrations, as well as the incidences of major neonatal complications, did not differ significantly between groups.
Conclusions:
In preterm infants born at less than 32 weeks' gestation, 500 IU/day and 900 IU/day VD supplementation were associated with similar serum 25(OH)D concentrations and broadly comparable calcium-phosphorus biochemical findings by 4 weeks of postnatal age. The 900 IU/day regimen was associated with higher ALP in some analyses, particularly in infants born at 28+0 to 31+6 weeks' gestation. These findings are limited to the first month after birth.
Related Concept Videos
Drug Dosing: Infants and Children
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Bioavailability Study Design: Single Versus Multiple Dose Studies
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Bioavailability Study Design: Healthy Subjects Versus Patients
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...